Summary
3.76 0.14(3.87%)06/27/2025
Perspective Therapeutics, Inc. (CATX)
CATX reported last earnings on 2025-05-12 after the market. An EPS of $-0.25 was observed compared to an estimated EPS of $-0.28, resulting in a surprise value of $0.03. A revenue of $0 million was observed compared to an estimated revenue of $0 million, resulting in a surprise value of $0 Million.
Perspective Therapeutics, Inc. (CATX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -7.45 | -8.52 | 56.67 | 63.48 | 17.87 | -61.90 | -32.37 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Fundamental Ratings
| Category | Rating |
| Main Rating | B- |
| Recommended Rating | Sell |
| DCF | Neutral |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Buy |
| P/E | Strong Sell |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 3.48 | |
| Open | 3.78 | |
| High | 3.78 | |
| Low | 3.48 | |
| Volume | 964,566 | |
| Change | -0.28 | |
| Change % | -7.45 | |
| Avg Volume (20 Days) | 1,838,743 | |
| Volume/Avg Volume (20 Days) Ratio | 0.52 | |
| 52 Week Range | 1.67 - 16.55 | |
| Price vs 52 Week High | -78.97% | |
| Price vs 52 Week Low | 108.38% | |
| Range | 0.00 | |
| Gap Up/Down | -0.26 | |
Profitibility | ||
| Market Capitalization (Mln) | 233 | |
| Revenue per share | 0.0000 | |
| Net Income per share | -1.1225 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -3.3498 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
06/21 08:00 EST - globenewswire.com
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug...
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug...
06/21 08:00 EST - globenewswire.com
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the...
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the...
05/30 17:21 EST - globenewswire.com
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced that updated interim results from its ongoing Phase 1/2a...
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced that updated interim results from its ongoing Phase 1/2a...
05/12 16:36 EST - globenewswire.com
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results
SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business...
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results
SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business...
05/01 07:00 EST - globenewswire.com
Perspective Therapeutics to Participate in Upcoming May Investor Conferences
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate...
Perspective Therapeutics to Participate in Upcoming May Investor Conferences
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate...
04/23 12:25 EST - globenewswire.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company's [212Pb]VMT-α-NET and...
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company's [212Pb]VMT-α-NET and...
04/17 07:00 EST - globenewswire.com
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
SEATTLE, April 17, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its first quarter 2025...
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
SEATTLE, April 17, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its first quarter 2025...
04/11 07:00 EST - globenewswire.com
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a...
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a...
04/02 10:35 EST - zacks.com
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
03/31 07:00 EST - globenewswire.com
Perspective Therapeutics to Participate in Upcoming April Investor Conferences
SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership...
Perspective Therapeutics to Participate in Upcoming April Investor Conferences
SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership...
03/26 16:10 EST - globenewswire.com
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results
SEATTLE, March 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today...
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results
SEATTLE, March 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today...
03/17 07:00 EST - globenewswire.com
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a...
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a...
02/26 07:00 EST - globenewswire.com
Perspective Therapeutics to Present at Upcoming March Investor Conferences
SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior...
Perspective Therapeutics to Present at Upcoming March Investor Conferences
SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior...
02/21 07:00 EST - globenewswire.com
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will...
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will...
02/05 07:00 EST - globenewswire.com
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership...
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership...
01/24 07:00 EST - globenewswire.com
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [ 212 Pb]VMT-α-NET [ 212 Pb]VMT-α-NET continued to have a favorable safety profile, with no...
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [ 212 Pb]VMT-α-NET [ 212 Pb]VMT-α-NET continued to have a favorable safety profile, with no...
01/06 08:00 EST - globenewswire.com
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan...
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan...
12/23 11:13 EST - seekingalpha.com
Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM
Perspective Therapeutics' radiopharmaceuticals offer potential oncology applications by combining diagnostics with targeted therapeutics. I like the company's theranostics approach that delivers radiation directly to tumors. This can potentially minimize healthy tissue damage, and it has already...
Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM
Perspective Therapeutics' radiopharmaceuticals offer potential oncology applications by combining diagnostics with targeted therapeutics. I like the company's theranostics approach that delivers radiation directly to tumors. This can potentially minimize healthy tissue damage, and it has already...
12/20 16:16 EST - seekingalpha.com
Perspective Therapeutics: Definitely Not Looking Overvalued Now
Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to continue research for years, despite current market skepticism and a significant drop in valuation....
Perspective Therapeutics: Definitely Not Looking Overvalued Now
Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to continue research for years, despite current market skepticism and a significant drop in valuation....
11/27 07:00 EST - globenewswire.com
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior...
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior...